$AERO

Seth Klarman Stock Portfolio: 10 Best Stocks to Buy

The article profiles Seth Klarman and Baupost Group, citing Bloomberg and CNBC comments on requiring investment catalysts and being cautious about AI-driven valuation risk. It then builds a “top holdings” list from Baupost’s Q1 2026 portfolio, using analyst 12-month price targets and 13F sentiment. Example stocks include Aeromexico (AERO) and Herbalife (HLF) with upside estimates of 54.37% and 60.18%.

Original reporting
Published Jul 8, 2026, 1:45 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 8, 2026, 2:37 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Seth Klarman Stock Portfolio: 10 Best Stocks to Buy — source image
Decision brief

The 30-second read

$AERONeutralLow
01

Why it matters

The newest concrete facts are (1) Jefferies initiating coverage on Aeromexico with a Hold and $20 target, and (2) Herbalife and IIT Madras inaugurating a plant cell fermentation research center. Neither includes earnings, guidance, or contract-level financial disclosures.

02

Market read

This is more of a stock-picking and catalyst-light roundup than a fundamental newswire; trading value is mainly around analyst initiation sentiment and long-horizon R&D optics.

03

What to watch

For AERO, regulatory limits and Mexico competition are explicitly flagged, which can cap upside from a single initiation. For HLF, the center’s impact depends on future commercialization, which the article does not quantify.

Relevance 4/10Novelty 3/10Timing: after-hours or next-session positioning around analyst initiation and the research-center announcement

Background

The piece frames Seth Klarman’s Baupost approach and then lists “top holdings” from Q1 2026, using analyst upside targets and 13F sentiment.

Company-level read

Ticker impact

$AERONeutralMedium confidence
Context

Jefferies initiated coverage on Aeromexico with a Hold rating and a $20 price target, citing route network and premium fares.

Expected impact

Likely modest, sentiment-driven reaction around initiation and target discussion; follow-through depends on subsequent earnings and route/regulatory developments.

Evidence & confidence

The article provides a specific initiation, rating, and target, but no new operational or financial datapoint beyond the analyst thesis.

$HLFBullishLow confidence
Context

Herbalife subsidiary and IIT Madras inaugurated a Herbalife-IIT Center of Excellence for plant cell fermentation research in Chennai.

Expected impact

Near-term impact likely limited; any price reaction would be small unless investors view it as accelerating product pipeline monetization.

Evidence & confidence

The article describes an inauguration and stated goals, but provides no revenue, margin, or timeline metrics that would directly reprice the stock.

Market effects

Airline read-through is limited to valuation framing versus peers; biomanufacturing research read-through is limited to long-dated pipeline expectations.

India academic-industry collaboration could modestly support sentiment around plant-based biomanufacturing, but no direct India revenue impact is quantified.

No direct global macro or cross-asset linkage beyond general AI bubble discussion in the introduction.

Counterpoint

These are promotional-style “best stocks” selections with catalysts that are either analyst-initiated (AERO) or research-focused (HLF), so near-term repricing may be overstated.

Key entities

  • Baupost Group

    Seth Klarman’s fund; the article claims the list is based on its Q1 2026 portfolio holdings.

  • Jefferies

    Initiated coverage on Aeromexico with a Hold rating and $20 price target.

  • Herbalife India and IIT Madras

    Inaugurated a Center of Excellence for plant cell fermentation research.

Related articles

$HLFHigh

Why Herbalife (HLF) Stock Is Nosediving

Herbalife (HLF) stock fell 13.2% after CEO Stephan Gratziani announced his departure, effective October 31, 2026. CFO John DeSimone will serve as interim CEO. The company's shares are down 14.2% YTD and 44.9% from their 52-week high. Argus Research previously upgraded HLF to 'Buy' with a $15 price target, citing expected revenue growth from new products.

$HLFHigh

Why is Herbalife stock tumbling today?

Herbalife (HLF) stock fell 12.7% after announcing CEO Stephan Gratziani will step down by October 31, 2026, with CFO John DeSimone as interim CEO. The company reaffirmed its Q3 and full-year 2026 financial guidance, projecting net sales growth of 0.5% to 4.5% and adjusted EBITDA of $160M to $180M. Broader market declines and geopolitical tensions also contributed to the sell-off.

$HLFMedAI 8/10

Herbalife stock tumbles as CEO Gratziani to step down in 2026

Herbalife Ltd (NYSE: HLF) shares dropped 12.5% after announcing CEO Stephan Gratziani will step down in 2026. He will transition to a consultant role, and CFO John DeSimone will serve as interim CEO. The company reaffirmed its 2026 financial guidance, expecting YoY net sales growth and adjusted EBITDA of $670M-$690M for the full year.

$DALMedAI 8/10

Delta Air Lines (DAL) vs. Grupo Aeroméxico (AERO): Which Airline Stock is Better Positioned after the Cross-Border Partnership Win?

Delta Air Lines (DAL) and Grupo Aeroméxico (AERO) secured a regulatory win, preserving their cross-border partnership. Delta reported Q2 2026 revenue of $17.7B, a 9.4% operating margin, and $1.9B in operating income. Aeroméxico reported $1.5B in revenue but faced higher fuel costs, resulting in a 4.6% operating margin. Delta's stronger financial performance and institutional backing make it a better investment choice, according to the analysis.

$HLFMedAI 8/10

Herbalife (NYSE:HLF) Beats Q2 CY2026 Sales Expectations

Herbalife (NYSE:HLF) reported Q2 CY2026 revenue of $1.33 billion, up 5.4% year on year and about 1.5% above Wall Street estimates, according to the company. It guided next-quarter revenue near $1.31 billion. Non-GAAP EPS was $0.51, missing consensus by 4.9%. Shares fell 3.4% to $12.16 after results.